Filtered By:
Drug: Melatonin

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Recent strategies for drug development in fibromyalgia syndrome.
Authors: Blumenthal DE, Malemud CJ Abstract INTRODUCTION: The US Federal Drug Administration (FDA) approved 3 medications for treating fibromyalgia syndrome (FMS). There have been no additional FDA approvals since January 2009 and the efficacy of the FDA-approved medications for FMS has been questioned. AREAS COVERED: The "search for studies" tool using clinicaltrials.gov and PubMed were employed. The term, "fibromyalgia" was used for clinicaltrials.gov. The terms employed for PubMed were "Name-of-Drug Fibromyalgia", "Fibromyalgia Treatment" or "Fibromyalgia Drug Treatment." Clinical trials were reviewed if the...
Source: Expert Review of Neurotherapeutics - July 1, 2016 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Potential drug therapies for the treatment of fibromyalgia.
Authors: Lawson K Abstract INTRODUCTION: Fibromyalgia (FM) is a common, complex chronic widespread pain condition is characterized by fatigue, sleep disturbance and cognitive dysfunction. Treatment of FM is difficult, requiring both pharmacological and non-pharmacological approaches, with an empiric approach to drug therapy focused toward individual symptoms, particularly pain. The effectiveness of current medications is limited with many patients discontinuing use. AREAS COVERED: A systemic database search has identified 26 molecular entities as potential emerging drug therapies. Advances in the understanding ...
Source: Expert Opinion on Investigational Drugs - June 11, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Melatonin in Chronic Pain Syndromes
Abstract Melatonin is a neurohormone secreted by epiphysis and extrapineal structures. It performs several functions including chronobiotic, antioxidant, oncostatic, immune modulating, normothermal, and anxiolytic functions. Melatonin affects the cardiovascular system and gastrointestinal tract, participates in reproduction and metabolism, and body mass regulation. Moreover, recent studies have demonstrated melatonin efficacy in relation to pain syndromes. The present paper reviews the studies on melatonin use in fibromyalgia, headaches, irritable bowel syndrome, chronic back pain, and rheumatoid arthritis. The pa...
Source: Pain and Therapy - March 16, 2016 Category: Anesthesiology Source Type: research

Fibromyalgia and bipolar disorder: emerging epidemiological associations and shared pathophysiology.
Abstract Fibromyalgia (FM) is a prevalent disorder defined by the presence of chronic widespread pain in association with fatigue, sleep disturbances and cognitive dysfunction. Recent studies indicate that bipolar spectrum disorders frequently co-occur in individuals with FM. Furthermore, shared pathophysiological mechanisms anticipate remarkable phenomenological similarities between FM and BD. A comprehensive search of the English literature was carried out in the Pubmed/MEDLINE database through May 10th, 2015 to identify unique references pertaining to the epidemiology and shared pathophysiology between FM and b...
Source: Current Molecular Medicine - January 26, 2016 Category: Molecular Biology Authors: Bortolato B, Berk M, Maes M, McIntyre RS, Carvalho AF Tags: Curr Mol Med Source Type: research

Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.
CONCLUSION: Melatonin increased the inhibitory endogenous pain-modulating system as assessed by the reduction on NPS(0-10) during the CPM-TASK. Melatonin alone or associated with amitriptyline was better than amitriptyline alone in improving pain on the VAS, whereas its association with amitriptyline produced only marginal additional clinical effects on FIQ and PPT. TRIAL REGISTRATION: Current controlled trail is registered at clinical trials.gov upon under number NCT02041455. Registered January 16, 2014. PMID: 25052847 [PubMed - indexed for MEDLINE]
Source: BMC Pharmacology and Toxicology - November 20, 2015 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research

Immunomodulatory Effects Mediated by Serotonin.
Authors: Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, Quintero-Fabian S, Pavón L Abstract Serotonin (5-HT) induces concentration-dependent metabolic effects in diverse cell types, including neurons, entherochromaffin cells, adipocytes, pancreatic beta-cells, fibroblasts, smooth muscle cells, epithelial cells, and leukocytes. Three classes of genes regulating 5-HT function are constitutively expressed or induced in these cells: (a) membrane proteins that regulate the response to 5-HT, such as SERT, 5HTR-GPCR, and the 5HT3-ion channels; (b) downstre...
Source: Journal of Immunology Research - May 13, 2015 Category: Allergy & Immunology Tags: J Immunol Res Source Type: research

The gut–brain axis: The role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions
Publication date: Available online 20 January 2015 Source:Advances in Integrative Medicine Author(s): George Anderson , Michael Maes Recent work has highlighted the importance of immune inflammatory processes, oxidative and nitrosative stress (O&NS) and tryptophan catabolites (TRYCATs) in the aetiology of depression and many depression-associated disorders, including other psychiatric, neurodegenerative and wider medical disorders. A recently researched aspect of the aetiology and course of depression has focussed on the role of gut permeability and gut microbiota. Increased gut permeability is evident in many me...
Source: Advances in Integrative Medicine - January 22, 2015 Category: Internal Medicine Source Type: research

Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial
Background: Central disinhibition is a mechanism involved in the physiopathology of fibromyalgia. Melatonin can improve sleep quality, pain and pain threshold. We hypothesized that treatment with melatonin alone or in combination with amitriptyline would be superior to amitriptyline alone in modifying the endogenous pain-modulating system (PMS) as quantified by conditional pain modulation (CPM), and this change in CPM could be associated with serum brain-derived neurotrophic factor (BDNF). We also tested whether melatonin improves the clinical symptoms of pain, pain threshold and sleep quality. Methods: Sixty-three females...
Source: BMC Clinical Pharmacology - July 23, 2014 Category: Drugs & Pharmacology Authors: Simone de ZanetteRafael VercelinoGabriela LasteJoanna RoziskyAndré SchwertnerCaroline MachadoFernando XavierIzabel de SouzaAlicia DeitosIraci TorresWolnei Caumo Source Type: research

Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders.
Abstract In many psychiatric, neurodegenerative and systemic inflammatory disorders circadian melatonin is decreased whilst melatonin enzymes and melatonin receptors are genetic susceptibility factors. Treatment with melatonin is useful in a diverse range of medical conditions, including bipolar disorder, Alzheimer's disease, depression and fibromyalgia. Decreased melatonin effects are classically attributed to lost pineal production. However, melatonin, along with its immediate precursor N-acetylserotonin (NAS), is produced by many, if not all, mitochondrial containing cells, including immune cells and central gl...
Source: CNS and Neurological Disorders Drug Targets - July 10, 2014 Category: Drugs & Pharmacology Authors: Anderson G, Maes M Tags: CNS Neurol Disord Drug Targets Source Type: research

Melatonin in antinociception: its therapeutic applications.
Abstract The intensity of pain sensation exhibits marked day and night variations. Since the intensity of pain perception is low during dark hours of the night when melatonin levels are high, this hormone has been implicated as one of the prime antinociceptive substances. A number of studies have examined the antinociceptive role of melatonin in acute, inflammatory and neuropathic pain animal models. It has been demonstrated that melatonin exerts antinociceptive actions by acting at both spinal cord and supraspinal levels. The mechanism of antinociceptive actions of melatonin involves opioid, benzodiazepine, α(1)...
Source: Current Neuropharmacology - June 1, 2012 Category: Drugs & Pharmacology Authors: Srinivasan V, Lauterbach EC, Ho KY, Acuña-Castroviejo D, Zakaria R, Brzezinski A Tags: Curr Neuropharmacol Source Type: research